publication date: Jan. 25, 2017

Ovarian Cancer NewVac Meets Primary Endpoints in Phase II Trial of Quisinostat Combination in Platinum-Resistant Disease

NewVac LLC reported meeting all primary endpoints in the phase II Clinical Trial of Quisinostat, novel selective oral histone deacetylase inhibitor, which NewVac licensed from Janssen Pharmaceutica NV.

The clinical trial is evaluating the efficacy and safety of Quisinostat in platinum-resistant ovarian cancer in combination with Paclitaxel and Carboplatin. The detailed results will be presented in a clinical research meeting this year.

The main advantage of Quisinostat – its unique pharmacokinetic properties, particularly the ability to selectively accumulate in target tissues, providing high potential in treatment of solid tumors, which has been demonstrated in the phase II trial.

Quisinostat may present a safe and effective therapeutic solution to patients by restoring sensitivity to chemotherapy in platinum-resistant cases. The efficacy and safety of Quisinostat will be further explored in clinic. In 2016 chemistry, manufacturing, and control activities were initiated to support a Phase III clinical trial. The results of a Quisinostat phase Ib clinical trial were recently presented at the European Society for Medical Oncology 2016 scientific congress in Copenhagen.

Quisinostat demonstrated good safety profile and promising efficacy in metastatic platinum-resistant ovarian cancer, showing the highest objective response rate, among other patient groups within the trial. Preclinical studies have shown that Quisinostat amplifies HDAC-repressed expression of E-cadherin, … Continue reading CCL Jan 2017 – NewVac Meets Primary Endpoints in Phase II Trial of Quisinostat Combination in Platinum-Resistant Disease

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.